Drug-Induced Kidney and Liver Injury
Drug-induced kidney and liver injury is a major problem throughout the world. Some of the most commonly prescribed drugs are involved in the pathogenesis of kidney and liver toxicity, including antibiotics, acetaminophen (Tylenol®), non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., ibuprofen [Advil®]), and angiotensin-converting enzyme (ACE) inhibitors. These frequently prescribed medications can result in kidney and liver toxicities, and many are available over the counter. Therefore, it is imperative that healthcare providers are aware of which agents commonly cause kidney or liver injury, symptoms that may indicate toxicity, abnormalities in lab values that indicate kidney or liver injury, and potential preventive measures.
The goal of this course is to provide healthcare professionals with in-depth understanding of common drugs and other agents that are nephrotoxic or hepatotoxic.
Drug-induced kidney and liver injury is a major problem throughout the world. Some of the most commonly prescribed drugs are involved in the pathogenesis of kidney and liver toxicity, including antibiotics, acetaminophen (Tylenol®), non-steroidal anti-inflammatory drugs (NSAIDs) (e.g., ibuprofen [Advil®]), and angiotensin-converting enzyme (ACE) inhibitors. These frequently prescribed medications can result in kidney and liver toxicities, and many are available over the counter. Therefore, it is imperative that healthcare providers are aware of which agents commonly cause kidney or liver injury, symptoms that may indicate toxicity, abnormalities in lab values that indicate kidney or liver injury, and potential preventive measures. The goal of this course is to provide healthcare professionals with in-depth understanding of common drugs and other agents that are nephrotoxic or hepatotoxic.
Accreditation Council for Continuing Medical Education
In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Relias LLC designates this enduring activity for a maximum of 1.75 AMA PRA category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center
In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nurses will receive 1.75 Nursing Contact Hours after successfully completing this course.
Arkansas State Board of Nursing
Arkansas State Board Of Nursing Approved Continuing Education program (CEBroker Provider #50-290).
Nurses will receive 1.75 contact hours for participating in this course.
District of Columbia Board of Nursing
District of Columbia Board of Nursing Approved Continuing Education program (CEBroker Provider #50-290).
Nurses will receive 1.7000 contact hours for participating in this course.
Florida Board of Medicine
Florida Board of Medicine (CEBroker Provider #50-290)
Physicians will receive 1.75 AMA PRA category 1 Credits™.
Florida Board of Nursing
Florida Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.5000 contact hours for participating in this course.
Florida Board of Pharmacy
Florida Board of Pharmacy (CEBroker Provider #50-290)
This module is approved for 1.75 contact hours.
Florida Physician Assistants
Florida Physician Assistants (CEBroker Provider #50-290)
Georgia Board of Nursing
Georgia Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.75 contact hours for participating in this course.
Kentucky Board of Nursing
Kentucky Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.75 contact hours for participating in this course.
Louisiana State Board of Medical Examiners
Louisiana State Board of Medical Examiners (CEBroker Provider #: 50-290)
Physicians will receive 1.75 AMA PRA category 1 Credits™.
Mississippi Board of Nursing
Mississippi Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.75 contact hours for participating in this course.
Mississippi State Board of Medical Licensure
Mississippi State Board of Medical Licensure (CEBroker Provider #: 50-290)
Physicians will receive 1.75 AMA PRA category 1 Credits™.
New Mexico Board of Nursing
New Mexico Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.75 contact hours for participating in this course.
North Dakota Board of Nursing
North Dakota Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.75 contact hours for participating in this course.
Ohio State Medical Board
State Medical Board of Ohio (CEBroker Provider #: 50-290)
Physicians will receive 1.75 AMA PRA category 1 Credits™.
South Carolina Board of Nursing
South Carolina Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.75 contact hours for participating in this course.
West Virginia Board of Registered Nursing
West Virginia Board of Registered Nursing (CEBroker Provider #50-290)
Nurses will receive 1.75 contact hours for participating in this course.
Examine the roles of healthcare professionals in the prevention and management of kidney and liver toxicity.
Identify drugs and supplements that commonly cause kidney and liver toxicity.
Express the pathogenesis for druginduced kidney and liver injury.
Outline:
Section 1: Introduction
About This Course
Learning Objectives
Section 2: Kidney and Liver Toxicity in Healthcare
Kidney and Liver Toxicity
Case Study
Roles of Each Healthcare Professional
Section 3: Drug-Induced Kidney Injury
Acute Kidney Injury
Overview of Renal Physiology
Definition of Acute Kidney Injury
Pathophysiology of Acute Kidney Injury
Detecting Acute Kidney Injury
Risk Factors for DrugInduced Acute Kidney Injury
Preventive Measures
Drugs Causing Kidney Toxicity
Important Equations
Section 4: Drug-Induced Liver Injury
Liver Injury
Risk Factors
Diagnosis
Monitoring and Treatment for DILI
Section 5: Drugs Causing Liver Toxicity
Intrinsic Drug Reactions
Idiosyncratic Drug Reactions
Review of Patient Case Study
Section 6: Clinical Vignette
Analyzing Nicole’s Case
Section 7: Conclusion
Course Summary
Course Contributors
Resources
References
Subject Matter Expert: Dr. Jennifer Gibson PharmDSooa Devereaux, MSN, RN, has a long history of professional development experience within the hospital setting. She has taught in pre-licensure nursing programs and has mentored many nurses, both new graduate and experienced, throughout her career as a nurse educator. Sooa is a Lead SME Writer at Relias and holds an MSN in Nursing Education.
Dr. Gibson is a pharmacist and medical communicator. She trained as a hospital pharmacist specializing in internal medicine and acute care. In this role, she helped implement patient safety initiatives and investigate medication errors and adverse drug reactions in hospital settings. She evaluates and consults on clinical performance and risk reduction in the healthcare industry and in other high-reliability organizations.
The target audience for this course is: Nurses; Physicians; in the following settings: Acute Care Facility.
Asynchronous/Online Distance Learning; please see certificate details for specifics on delivery format.
Relias has a grievance policy in place to facilitate reports of dissatisfaction. Relias will make every effort to resolve each grievance in a mutually satisfactory manner. In order to report a complaint or grievance please contact Relias.
If you require special accommodations to complete this module, please contact Relias Support by completing the web form (https://www.relias.com/help) or by using the chat functionality.
All courses offered by Relias, LLC are developed from a foundation of diversity, inclusiveness, and a multicultural perspective. Knowledge, values and awareness related to cultural competency are infused throughout the course content.
Reference herein to any specific commercial product, process, or service by trade name, trademark, service mark, manufacturer or otherwise does not constitute or imply any endorsement, recommendation, or favoring of, or affiliation with, Relias, LLC.
All characteristics and organizations referenced in the following training are fictional. Any resemblance to any actual organizations or persons living or dead, is purely coincidental.
To earn continuing education credit for this course you must achieve a passing score of 80% on the post-test and complete the course evaluation.
If you require special accommodations to complete this module, please contact Relias Customer Support here.
